Skip Navigation

JNCI Journal of the National Cancer Institute 2002 94(15):1172; doi:10.1093/jnci/94.15.1172
© 2002 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Malayeri, R.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Malayeri, R.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 94, No. 15, 1172, August 7, 2002
© 2002 Oxford University Press

CORRESPONDENCE

Re: Economic Analysis of Vinorelbine Plus Cisplatin Versus Paclitaxel Plus Carboplatin for Advanced Non-Small-Cell Lung Cancer

Reza Malayeri

Correspondence to: Reza Malayeri, M.D., Department of Academic Haematology, Royal Free Hospital, Pond St., London NW3 2PF, U.K. (e-mail: r.malayeri@rfc.ucl.ac.uk).

The first 10% of the full text of this article appears below.

In their paper, Ramsey et al. (1) describe an economic analysis of vinorelbine plus cisplatin versus paclitaxel plus carboplatin for advanced non-small-cell lung cancer. This analysis, however, . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?